Ischemic Heart Disease (IHD) Drugs Global Market Report 2024

Global Ischemic Heart Disease (IHD) Drugs Market Report 2024

Ischemic Heart Disease (IHD) Drugs Global Market Report 2024 – By Drug Class (Anti-Dyslipidemic Drugs, Calcium Channel Blockers, Beta-Blockers, Angiotensin-converting enzyme (ACE) Inhibitors, Angiotensin II Receptor Blockers (ARBs), Vasodilators, Antithrombotic Agents), By Disease Class (Angina Pectoris, Myocardial Infarction), By End User (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy) – Market Size, Trends, And Global Forecast 2024-2033

Name: Ischemic Heart Disease (IHD) Drugs Global Market Report 2024
Creator: The Business Research Company
License: https://www.thebusinessresearchcompany.com/privacy-policy

Ischemic Heart Disease (IHD) Drugs Global Market Report 2024

Starting Price : $5000.00 $4000.00 | Pages : 175 | Published : October 2024 | Delivery Time: 2-3 business days | Format : pdf

Purchase Options

Request a Sample

Request For Discount

Customise Your Report

Item added to cart!

Request For Proposal

Request For Regional Data

FAQs

Need assistance or more information before the purchase?

Enquire Before Buying

Ischemic Heart Disease (IHD) Drugs Global Market Report 2024

Proud Members Of

Ischemic Heart Disease (IHD) Drugs Market Definition

Ischemic heart disease (IHD) drugs are medications used to manage and treat a condition characterized by reduced blood flow to the heart muscle, often due to coronary artery narrowing. These drugs aim to alleviate symptoms, reduce the risk of complications such as heart attacks, and improve overall cardiac function.

The main types of drug classes included in ischemic heart disease (IHD) drugs are anti-dyslipidemic drugs, calcium channel blockers, beta-blockers, angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), vasodilators, and antithrombotic agents. Anti-dyslipidemic drugs are pharmacological agents that target and lower abnormal levels of lipids (such as cholesterol and triglycerides) in the bloodstream to reduce the risk of cardiovascular disease. These are used to treat various classes of disease, including angina pectoris and myocardial infarction, and are used by several end users, such as hospital pharmacies, retail pharmacies, and online pharmacies.

Ischemic Heart Disease (IHD) Drugs Market Segmentation

The ischemic heart disease (ihd) drugs market covered in this report is segmented –

1) By Drug Class: Anti-Dyslipidemic Drugs, Calcium Channel Blockers, Beta-Blockers, Angiotensin-converting enzyme (ACE) Inhibitors, Angiotensin II Receptor Blockers (ARBs), Vasodilators, Antithrombotic Agents

2) By Disease Class: Angina Pectoris, Myocardial Infarction

3) By End User: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

Global Ischemic Heart Disease IHD Drugs Market Size 2023 to 2028: Graph

Ischemic Heart Disease (IHD) Drugs Market Size 2024 And Growth Rate

The ischemic heart disease (ihd) drugs market size has grown strongly in recent years. It will grow from $6.02 billion in 2023 to $6.36 billion in 2024 at a compound annual growth rate (CAGR) of 5.7%. The growth in the historic period can be attributed to rising global prevalence of ischemic heart disease, increased awareness and diagnostics, changes in lifestyle and dietary patterns, government initiatives for cardiovascular health, collaborations for clinical trials, insurance coverage and reimbursement policies..

Ischemic Heart Disease (IHD) Drugs Market Growth Forecast

The ischemic heart disease (ihd) drugs market size is expected to see steady growth in the next few years. It will grow to $7.57 billion in 2028 at a compound annual growth rate (CAGR) of 4.4%. The growth in the forecast period can be attributed to aging population trends, personalized medicine approaches, emphasis on cardiovascular prevention, global health policies and initiatives, international research collaborations.. Major trends in the forecast period include shift towards precision medicine approaches, focus on novel anti-atherogenic agents, advancements in lipid-lowering therapies, integration of anti-inflammatory agents, development of antithrombotic and antiplatelet drugs..

Book your 30 minutes free consultation with our research experts

Ischemic Heart Disease (IHD) Drugs Market Driver: Rising Prevalence Of Obesity And Diabetes Fuels Expansion Of The Ischemic Heart Disease (IHD) Drugs Market

The growing prevalence of obesity and diabetes is expected to propel the growth of the ischemic heart disease (IHD) drugs market going forward. Diabetes is a long-term metabolic disease that causes high blood glucose levels, and obesity is a medical condition characterized by an excessive accumulation of body fat that can negatively impact health. Ischemic heart disease drugs are often used in individuals with obesity and diabetes to manage cardiovascular risk factors such as hypertension and dyslipidemia, mitigating the risk of ischemic heart disease. For instance, in March 2023, according to the World Obesity Federation, a UK-based not-for-profit organization, by 2035, obesity rates are expected to double among boys, reaching 208 million (a 100% increase), and more than double among girls, totaling 175 million (a 125% increase), as reported from 2020 levels. Further, It is estimated that the number of people living with obesity will reach 2.7 billion by 2025. Furthermore, in December 2021, according to the International Diabetes Federation, a US-based intergovernmental organization, diabetes affected 537 million adults (20–79 years old) in 2021, and it is predicted that the number would climb to 643 million people by 2030 and a total of 783 million by 2045. Therefore, the growing prevalence of obesity and diabetes drives the growth of the ischemic heart disease (IHD) drugs market.

Ischemic Heart Disease (IHD) Drugs Market Driver: Rising Heart Failure Cases Drive Surge In Ischemic Heart Disease (IHD) Drugs Market Growth

The increasing incidence of heart failure is expected to propel the growth of the ischemic heart disease (IHD) drug market going forward. Heart failure is a chronic condition in which the heart muscle is unable to pump enough blood to meet the body's needs for blood and oxygen. This can lead to fatigue, shortness of breath, and difficulty performing everyday activities. Ischemic heart disease (IHD) drugs play an important role in the treatment of heart failure. To reduce the risk factors and symptoms of ischemic heart disease, these medications can help avoid heart failure. Ischemic Heart Disease (IHD) drugs inhibit the pacemaker activity of the heart and are beneficial in heart failure patients with reduced ejection fractions and high resting heart rates after a tolerated beta-blocker. For instance, in September 2023, according to the Heart Failure Society of America, a US-based organization, 6.7 million Americans over 20 years of age have heart failure (HF), and the prevalence is expected to rise to 8.5 million Americans by 2030. Therefore, the increasing incidence of heart failure is driving the growth of the ischemic heart disease (IHD) drug market.

Global Ischemic Heart Disease (IHD) Drugs Market Major Players

Major companies operating in the ischemic heart disease (ihd) drugs market report are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, GSK PLC, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Viatris Inc., Baxter International Inc., Teva Pharmaceutical Industries Ltd., Sandoz Inc., Sun Pharmaceutical Industries Limited, Dr. Reddy's Laboratories Ltd., Cipla Limited, Lupin Limited, Recordati S.p.A., Zydus Lifesciences Limited, Glenmark Pharmaceuticals Ltd., Aurobindo Pharma Limited, Alembic Pharmaceuticals Ltd., Eagle Pharmaceuticals Inc., Accord Healthcare Limited, Macleods Pharmaceuticals Ltd., WG Critical Care LLC, Novitium Pharma LLC

Global Ischemic Heart Disease (IHD) Drugs Market Restraint: Hindrance of High Treatment Costs on the Ischemic Heart Disease (IHD) Drugs Market

The high cost of treatment can be a restraint for the ischemic heart disease (IHD) drugs market in the coming future, as it can limit access to care for patients who cannot afford the treatments. The high cost of IHD treatment can lead to delays in diagnosis and treatment, which can increase the risk of complications and impact the sales of IHD drugs. It can also make it difficult for patients to afford the care they need, which can lead to financial hardship. For instance, in August 2022, according to data published by GoodRx Health, a US-based healthcare company that operates a telemedicine platform, heart disease was one of the most expensive health conditions to treat in the US. Even with insurance, out-of-pocket expenses for a heart condition often exceed $2,000 a year. Atherosclerosis, or thickening or hardening of the arteries, can cause adults under the age of 65 to incur annual out-of-pocket medical expenses of more than $2,000 in addition to insurance premiums. The annual out-of-pocket expenses for patients with heart failure increase to $5,000. Therefore, the high cost of treatment is becoming a significant barrier to growth in the ischemic heart disease (IHD) drugs market.

Global Ischemic Heart Disease (IHD) Drugs Market Trend: Increasing Focus On Developing Intravenous P2Y12 Platelet Inhibitor To Gain A Competitive Advantage

Major companies operating in the ischemic heart disease (IHD) drugs market are increasing their focus on developing innovative platelet inhibitors, such as intravenous P2Y12 platelet inhibitors, to gain a competitive edge in the market. An intravenous P2Y12 platelet inhibitor is a medication administered directly into the bloodstream to prevent platelet activation and aggregation and reduce the risk of periprocedural myocardial infarction (MI), an ischemic heart disease. For instance, in October 2021, MSN Laboratories Private Limited, an India-based research-based pharmaceutical company, launched CANREAL injection (Cangrelor), the only intravenous P2Y12 platelet inhibitor with rapid onset and offset of platelet inhibition. It was developed to overcome both delayed and prolonged antiplatelet activity. It is a bioequivalent generic drug that is indicated as an adjunct to percutaneous coronary intervention to reduce the risk of myocardial infarction (MI).

Ischemic Heart Disease (IHD) Drugs Market Merger And Acquisition: Philip Morris International Expands 'Beyond Nicotine' Portfolio with Acquisition of OtiTopic Inc

In August 2021, Philip Morris International Inc., a US-based tobacco company, acquired OtiTopic Inc. for an undisclosed amount. With this acquisition, Philip Morris International will expand its portfolio of 'beyond nicotine' products and grow its pipeline of inhaled therapeutic products. OtiTopic Inc. is a US-based manufacturer of respiratory drugs for myocardial infarction (MI), a type of ischemic heart disease.

Regional Outlook For The Global Ischemic Heart Disease (IHD) Drugs Market

North America was the largest region in the ischemic heart disease (IHD) drugs market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the ischemic heart disease (ihd) drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the ischemic heart disease (IHD) drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

The ischemic heart disease (IHD) drugs market consists of sales of antiarrhythmic drugs, anticoagulants, anti-anginal medications, nitroglycerin and nitrates, statins, and antiplatelet agents. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

The ischemic heart disease (IHD) drugs market research report is one of a series of new reports from The Business Research Company that provides ischemic heart disease (IHD) drugs market statistics, including ischemic heart disease (IHD) drugs industry global market size, regional shares, competitors with a ischemic heart disease (IHD) drugs market share, detailed ischemic heart disease (IHD) drugs market segments, market trends and opportunities, and any further data you may need to thrive in the ischemic heart disease (IHD) drugs industry. This ischemic heart disease (IHD) drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Ischemic Heart Disease (IHD) Drugs Market Report Forecast and Analysis

Report Attribute	Details
Market Size Value In 2024	$6.36 billion
Revenue Forecast In 2033	$7.57 billion
Growth Rate	CAGR of 4.5% from 2024 to 2033
Base Year For Estimation	2023
Actual Estimates/Historical Data	2018-2023
Forecast Period	2024 - 2028 - 2033
Market Representation	Revenue in USD Billion and CAGR from 2024 to 2033
Segments Covered	1) By Drug Class: Anti-Dyslipidemic Drugs, Calcium Channel Blockers, Beta-Blockers, Angiotensin-converting enzyme (ACE) Inhibitors, Angiotensin II Receptor Blockers (ARBs), Vasodilators, Antithrombotic Agents 2) By Disease Class: Angina Pectoris, Myocardial Infarction 3) By End User: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy
Regional Scope	Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Country Scope	The countries covered in the report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain. Additional countries that can be covered in the report for an additional fee: Bangladesh, Thailand, Vietnam, Malaysia, Singapore, Philippines, Hong Kong, New Zealand, Mexico, Chile, Argentina, Colombia, Peru, Austria, Belgium, Denmark, Finland, Ireland, Netherlands, Norway, Portugal, Sweden, Switzerland, Czech Republic, Poland, Romania, Ukraine, Saudi Arabia, Israel, Iran, Turkey, UAE, Egypt, Nigeria, South Africa.
Key Companies Profiled	Pfizer Inc.; F. Hoffmann-La Roche Ltd.; Merck & Co. Inc.; AbbVie Inc.; Bayer AG; Novartis AG; Sanofi S.A.; Bristol-Myers Squibb Company; AstraZeneca PLC; GSK PLC; Eli Lilly and Company; Boehringer Ingelheim International GmbH; Viatris Inc.; Baxter International Inc.; Teva Pharmaceutical Industries Ltd.; Sandoz Inc.; Sun Pharmaceutical Industries Limited; Dr. Reddy's Laboratories Ltd.; Cipla Limited; Lupin Limited; Recordati S.p.A.; Zydus Lifesciences Limited; Glenmark Pharmaceuticals Ltd.; Aurobindo Pharma Limited; Alembic Pharmaceuticals Ltd.; Eagle Pharmaceuticals Inc.; Accord Healthcare Limited; Macleods Pharmaceuticals Ltd.; WG Critical Care LLC; Novitium Pharma LLC
Customization Scope	Request for Sample
Pricing And Purchase Options	Explore Purchase Options

1. Executive Summary

2. Ischemic Heart Disease (IHD) Drugs Market Characteristics

3. Ischemic Heart Disease (IHD) Drugs Market Trends And Strategies

4. Ischemic Heart Disease (IHD) Drugs Market - Macro Economic Scenario

4.1. Impact Of High Inflation On The Market

4.2. Ukraine-Russia War Impact On The Market

4.3. COVID-19 Impact On The Market

5. Global Ischemic Heart Disease (IHD) Drugs Market Size and Growth

5.1. Global Ischemic Heart Disease (IHD) Drugs Market Drivers and Restraints

5.1.1. Drivers Of The Market

5.1.2. Restraints Of The Market

5.2. Global Ischemic Heart Disease (IHD) Drugs Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)

5.3. Global Ischemic Heart Disease (IHD) Drugs Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Ischemic Heart Disease (IHD) Drugs Market Segmentation

6.1. Global Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Anti-Dyslipidemic Drugs

Calcium Channel Blockers

Beta-Blockers

Angiotensin-converting enzyme (ACE) Inhibitors

Angiotensin II Receptor Blockers (ARBs)

Vasodilators

Antithrombotic Agents

6.2. Global Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Angina Pectoris

Myocardial Infarction

6.3. Global Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Hospital Pharmacy

Retail Pharmacy

Online Pharmacy

7. Ischemic Heart Disease (IHD) Drugs Market Regional And Country Analysis

7.1. Global Ischemic Heart Disease (IHD) Drugs Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

7.2. Global Ischemic Heart Disease (IHD) Drugs Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Ischemic Heart Disease (IHD) Drugs Market

8.1. Asia-Pacific Ischemic Heart Disease (IHD) Drugs Market Overview

Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

8.2. Asia-Pacific Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8.3. Asia-Pacific Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8.4. Asia-Pacific Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Ischemic Heart Disease (IHD) Drugs Market

9.1. China Ischemic Heart Disease (IHD) Drugs Market Overview

9.2. China Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

9.3. China Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

9.4. China Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Ischemic Heart Disease (IHD) Drugs Market

10.1. India Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

10.2. India Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

10.3. India Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Ischemic Heart Disease (IHD) Drugs Market

11.1. Japan Ischemic Heart Disease (IHD) Drugs Market Overview

11.2. Japan Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11.3. Japan Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11.4. Japan Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Ischemic Heart Disease (IHD) Drugs Market

12.1. Australia Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12.2. Australia Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12.3. Australia Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Ischemic Heart Disease (IHD) Drugs Market

13.1. Indonesia Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13.2. Indonesia Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13.3. Indonesia Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Ischemic Heart Disease (IHD) Drugs Market

14.1. South Korea Ischemic Heart Disease (IHD) Drugs Market Overview

14.2. South Korea Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14.3. South Korea Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14.4. South Korea Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Ischemic Heart Disease (IHD) Drugs Market

15.1. Western Europe Ischemic Heart Disease (IHD) Drugs Market Overview

15.2. Western Europe Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15.3. Western Europe Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15.4. Western Europe Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Ischemic Heart Disease (IHD) Drugs Market

16.1. UK Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16.2. UK Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16.3. UK Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Ischemic Heart Disease (IHD) Drugs Market

17.1. Germany Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17.2. Germany Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17.3. Germany Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Ischemic Heart Disease (IHD) Drugs Market

18.1. France Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18.2. France Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18.3. France Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Ischemic Heart Disease (IHD) Drugs Market

19.1. Italy Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19.2. Italy Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19.3. Italy Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Ischemic Heart Disease (IHD) Drugs Market

20.1. Spain Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20.2. Spain Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20.3. Spain Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Ischemic Heart Disease (IHD) Drugs Market

21.1. Eastern Europe Ischemic Heart Disease (IHD) Drugs Market Overview

21.2. Eastern Europe Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21.3. Eastern Europe Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21.4. Eastern Europe Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Ischemic Heart Disease (IHD) Drugs Market

22.1. Russia Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22.2. Russia Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22.3. Russia Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Ischemic Heart Disease (IHD) Drugs Market

23.1. North America Ischemic Heart Disease (IHD) Drugs Market Overview

23.2. North America Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23.3. North America Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23.4. North America Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Ischemic Heart Disease (IHD) Drugs Market

24.1. USA Ischemic Heart Disease (IHD) Drugs Market Overview

24.2. USA Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24.3. USA Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24.4. USA Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Ischemic Heart Disease (IHD) Drugs Market

25.1. Canada Ischemic Heart Disease (IHD) Drugs Market Overview

25.2. Canada Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25.3. Canada Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25.4. Canada Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Ischemic Heart Disease (IHD) Drugs Market

26.1. South America Ischemic Heart Disease (IHD) Drugs Market Overview

26.2. South America Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26.3. South America Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26.4. South America Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Ischemic Heart Disease (IHD) Drugs Market

27.1. Brazil Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27.2. Brazil Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27.3. Brazil Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Ischemic Heart Disease (IHD) Drugs Market

28.1. Middle East Ischemic Heart Disease (IHD) Drugs Market Overview

28.2. Middle East Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28.3. Middle East Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28.4. Middle East Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Ischemic Heart Disease (IHD) Drugs Market

29.1. Africa Ischemic Heart Disease (IHD) Drugs Market Overview

29.2. Africa Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29.3. Africa Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29.4. Africa Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Ischemic Heart Disease (IHD) Drugs Market Competitive Landscape And Company Profiles

30.1. Ischemic Heart Disease (IHD) Drugs Market Competitive Landscape

30.2. Ischemic Heart Disease (IHD) Drugs Market Company Profiles

30.2.1. Pfizer Inc.

30.2.1.1. Overview

30.2.1.2. Products and Services

30.2.1.3. Strategy

30.2.1.4. Financial Performance

30.2.2. F. Hoffmann-La Roche Ltd.

30.2.2.1. Overview

30.2.2.2. Products and Services

30.2.2.3. Strategy

30.2.2.4. Financial Performance

30.2.3. Merck & Co. Inc.

30.2.3.1. Overview

30.2.3.2. Products and Services

30.2.3.3. Strategy

30.2.3.4. Financial Performance

30.2.4. AbbVie Inc.

30.2.4.1. Overview

30.2.4.2. Products and Services

30.2.4.3. Strategy

30.2.4.4. Financial Performance

30.2.5. Bayer AG

30.2.5.1. Overview

30.2.5.2. Products and Services

30.2.5.3. Strategy

30.2.5.4. Financial Performance

31. Ischemic Heart Disease (IHD) Drugs Market Other Major And Innovative Companies

31.1. Novartis AG

31.2. Sanofi S.A.

31.3. Bristol-Myers Squibb Company

31.4. AstraZeneca PLC

31.5. GSK PLC

31.6. Eli Lilly and Company

31.7. Boehringer Ingelheim International GmbH

31.8. Viatris Inc.

31.9. Baxter International Inc.

31.10. Teva Pharmaceutical Industries Ltd.

31.11. Sandoz Inc.

31.12. Sun Pharmaceutical Industries Limited

31.13. Dr. Reddy's Laboratories Ltd.

31.14. Cipla Limited

31.15. Lupin Limited

32. Global Ischemic Heart Disease (IHD) Drugs Market Competitive Benchmarking

33. Global Ischemic Heart Disease (IHD) Drugs Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Ischemic Heart Disease (IHD) Drugs Market

35. Ischemic Heart Disease (IHD) Drugs Market Future Outlook and Potential Analysis

35.1 Ischemic Heart Disease (IHD) Drugs Market In 2028 - Countries Offering Most New Opportunities

35.2 Ischemic Heart Disease (IHD) Drugs Market In 2028 - Segments Offering Most New Opportunities

35.3 Ischemic Heart Disease (IHD) Drugs Market In 2028 - Growth Strategies

35.3.1 Market Trend Based Strategies

35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations

36.2. Currencies

36.3. Historic And Forecast Inflation Rates

36.4. Research Inquiries

36.5. The Business Research Company

36.6. Copyright And Disclaimer

List Of Tables

Table 1: Global Historic Market Growth, 2018-2023, $ Billion

Table 2: Global Forecast Market Growth, 2023-2028F, 2033F, $ Billion

Table 3: Global Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 4: Global Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 5: Global Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 6: Global Ischemic Heart Disease (IHD) Drugs Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 7: Global Ischemic Heart Disease (IHD) Drugs Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 8: Asia-Pacific, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 9: Asia-Pacific, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 10: Asia-Pacific, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 11: China, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 12: China, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 13: China, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 14: India, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 15: India, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 16: India, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 17: Japan, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 18: Japan, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 19: Japan, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 20: Australia, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 21: Australia, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 22: Australia, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 23: Indonesia, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 24: Indonesia, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 25: Indonesia, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 26: South Korea, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 27: South Korea, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 28: South Korea, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 29: Western Europe, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 30: Western Europe, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 31: Western Europe, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 32: UK, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 33: UK, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 34: UK, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 35: Germany, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 36: Germany, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 37: Germany, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 38: France, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 39: France, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 40: France, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 41: Italy, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 42: Italy, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 43: Italy, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 44: Spain, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 45: Spain, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 46: Spain, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 47: Eastern Europe, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 48: Eastern Europe, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 49: Eastern Europe, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 50: Russia, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 51: Russia, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 52: Russia, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 53: North America, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 54: North America, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 55: North America, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 56: USA, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 57: USA, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 58: USA, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 59: Canada, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 60: Canada, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 61: Canada, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 62: South America, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 63: South America, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 64: South America, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 65: Brazil, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 66: Brazil, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 67: Brazil, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 68: Middle East, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 69: Middle East, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 70: Middle East, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 71: Africa, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 72: Africa, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 73: Africa, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 74: Pfizer Inc. Financial Performance

Table 75: F. Hoffmann-La Roche Ltd. Financial Performance

Table 76: Merck & Co. Inc. Financial Performance

Table 77: AbbVie Inc. Financial Performance

Table 78: Bayer AG Financial Performance

List Of Figures

Figure 1: Global Historic Market Growth, 2018-2023, $ Billion

Figure 2: Global Forecast Market Growth, 2023-2028F, 2033F, $ Billion

Figure 3: Global Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 4: Global Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 5: Global Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 6: Global Ischemic Heart Disease (IHD) Drugs Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 7: Global Ischemic Heart Disease (IHD) Drugs Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 8: Asia-Pacific, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 9: Asia-Pacific, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 10: Asia-Pacific, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 11: China, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 12: China, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 13: China, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 14: India, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 15: India, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 16: India, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 17: Japan, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 18: Japan, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 19: Japan, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 20: Australia, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 21: Australia, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 22: Australia, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 23: Indonesia, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 24: Indonesia, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 25: Indonesia, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 26: South Korea, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 27: South Korea, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 28: South Korea, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 29: Western Europe, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 30: Western Europe, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 31: Western Europe, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 32: UK, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 33: UK, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 34: UK, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 35: Germany, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 36: Germany, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 37: Germany, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 38: France, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 39: France, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 40: France, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 41: Italy, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 42: Italy, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 43: Italy, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 44: Spain, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 45: Spain, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 46: Spain, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 47: Eastern Europe, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 48: Eastern Europe, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 49: Eastern Europe, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 50: Russia, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 51: Russia, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 52: Russia, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 53: North America, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 54: North America, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 55: North America, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 56: USA, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 57: USA, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 58: USA, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 59: Canada, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 60: Canada, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 61: Canada, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 62: South America, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 63: South America, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 64: South America, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 65: Brazil, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 66: Brazil, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 67: Brazil, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 68: Middle East, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 69: Middle East, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 70: Middle East, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 71: Africa, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 72: Africa, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 73: Africa, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 74: Pfizer Inc. Financial Performance

Figure 75: F. Hoffmann-La Roche Ltd. Financial Performance

Figure 76: Merck & Co. Inc. Financial Performance

Figure 77: AbbVie Inc. Financial Performance

Figure 78: Bayer AG Financial Performance

Global Protein Purification And Isolation Market 2022 – Market Opportunities And Strategies

What Is The Pharmaceutical Processing Seals Market Overview In 2022?

The Plasma Fractionation Market Share, Market Size, And Growth Rate 2022

The Biosimilar Therapeutic Peptides Market Share, Market Size, And Growth Rate 2022

The Business Research Company offers the plasma fractionation market research report 2022 with industry size, share, segments and market growth

The Business Research Company offers the stem cell therapy market research report 2022 with industry size, share, segments and market growth

The Business Research Company offers the regenerative medicine for cartilage market research report 2022 with industry size, share, segments and market growth

The Business Research Company offers the covid-19 current therapy market research report 2022 with industry size, share, segments and market growth

Antiparasitic Drugs Global Market Report 2024 – By Product Type (Anthelmintics, Antiprotozoals, Ectoparasiticide, Other Products), By Treatment (Avermectins, Bezimidazoles, Pyrimidines, Organophosphates, Imidazolesthiazoles), By Route of Administration (Oral, Injectable, Topical), By End User (Hospitals, Homecare, Specialty Clinics, Other End Users) – Market Size, Trends, And Global Forecast 2024-2033

View Report

Congenital Diaphragmatic Hernia Drugs Global Market Report 2024 – By Type (Posterolateral Bochdalek Hernia, Anterior Morgagni Hernia, Hiatal Hernia), By Treatment (Extracorporeal Membrane Oxygenation, Other Treatments), By Diagnosis (Prenatal, Postnatal), By End-User (Hospitals, Homecare, Specialty Clinics, Other End Users) – Market Size, Trends, And Global Forecast 2024-2033

View Report

Complicated Skin And Skin Structure Infections Drugs Global Market Report 2024 – By Active Ingredients (Delafloxacin, Vancomycin, Ceftaroline Fosamil, Linezolid, Other Active Ingredients), By Route of Administration (Oral, Topical, Parenteral), By End User (Hospitals, Homecare, Specialty Clinics, Other End-Users) – Market Size, Trends, And Global Forecast 2024-2033

View Report

Otic Drugs Global Market Report 2024 – By Drug Class (Cerumenolytics, Otic Anesthetics, Otic Anti-Infectives, Otic Steroids, Other Drug Class), By Indication (Otitis, Middle Ear Infections, Other Indication), By Route of Administration (Oral, Topical, Injectable, Other Route of Administration), By End-Users (Hospitals, Specialty Clinics, Homecare, Other End-Users) – Market Size, Trends, And Global Forecast 2024-2033

View Report

Preeclampsia Drugs Global Market Report 2024 – By Type (Mild Preeclampsia, Severe Preeclampsia), By Treatment (Medication to Lower Hypertension (B.P), Corticosteroids, Anticonvulsants Medication), By Route of Administration (Oral, Parenteral, Other Route of Administration), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacies, Other Distribution Channels), By End-User (Hospitals, Specialty Clinics, Diagnostic Centers, Other End-Users) – Market Size, Trends, And Global Forecast 2024-2033

View Report

Myelodysplastic Syndrome (MDS) Drugs Global Market Report 2024 – By Drug Type (Chemotherapy, Immunomodulatory Drugs), By Route Of Administration (Oral, Parenteral), By Syndrome (Refractory Cytopenia With Multilineage Dysplasia, Refractory Anemia, Refractory Anemia With Ringed Sideroblasts), By End User (Hospitals, Clinics, Ambulatory Surgical Centers) – Market Size, Trends, And Global Forecast 2024-2033

View Report

Narcotic Drugs Global Market Report 2024 – By Drug (Opium, Heroin, Codeine, Oxycodone, Other Drugs), By Source (Natural, Semi-Synthetic, Synthetic), By Indication (Pain Management, Cough, Diarrhea, Dysentery, Asthma, Other Indications), By Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy), By End User (Hospitals, Homecare, Specialty Clinics, Other End Users) – Market Size, Trends, And Global Forecast 2024-2033

View Report

Focal Segmental Glomerulosclerosis Drugs Global Market Report 2024 – By Type (Losmapimod, SHP-627, Sparsentan, TM-5484, Other Types), By Treatment (Corticosteroids, Immunosuppressive Drugs, Angiotensin Converting Enzymes (ACE) Inhibitors, A.R. Blockers, Diuretics, Other Treatments), By Route of Administration (Oral, Parenteral), By End User (Hospitals, Homecare, Specialty Clinics, Other End Users) – Market Size, Trends, And Global Forecast 2024-2033

View Report

Frequently Asked Questions

What is the definition of the ischemic heart disease IHD drugs market?

How will the ischemic heart disease IHD drugs market drivers and restraints affect the ischemic heart disease IHD drugs market dynamics? What forces will shape the ischemic heart disease IHD drugs industry going forward?

The ischemic heart disease IHD drugs market major growth driver - rising prevalence of obesity and diabetes fuels expansion of the ischemic heart disease (ihd) drugs market. For further insights on the ischemic heart disease IHD drugs market, request a sample here

What is the forecast market size or the forecast market value of the ischemic heart disease IHD drugs market ?

The ischemic heart disease (ihd) drugs market size has grown strongly in recent years. It will grow from $6.02 billion in 2023 to $6.36 billion in 2024 at a compound annual growth rate (CAGR) of 5.7%. The growth in the historic period can be attributed to rising global prevalence of ischemic heart disease, increased awareness and diagnostics, changes in lifestyle and dietary patterns, government initiatives for cardiovascular health, collaborations for clinical trials, insurance coverage and reimbursement policies.. The ischemic heart disease (ihd) drugs market size is expected to see steady growth in the next few years. It will grow to $7.57 billion in 2028 at a compound annual growth rate (CAGR) of 4.4%. The growth in the forecast period can be attributed to aging population trends, personalized medicine approaches, emphasis on cardiovascular prevention, global health policies and initiatives, international research collaborations.. Major trends in the forecast period include shift towards precision medicine approaches, focus on novel anti-atherogenic agents, advancements in lipid-lowering therapies, integration of anti-inflammatory agents, development of antithrombotic and antiplatelet drugs.. For further insights on the ischemic heart disease IHD drugs market, request a sample here

How is the ischemic heart disease IHD drugs market segmented?

The ischemic heart disease IHD drugs market is segmented
1) By Drug Class: Anti-Dyslipidemic Drugs, Calcium Channel Blockers, Beta-Blockers, Angiotensin-converting enzyme (ACE) Inhibitors, Angiotensin II Receptor Blockers (ARBs), Vasodilators, Antithrombotic Agents
2) By Disease Class: Angina Pectoris, Myocardial Infarction
3) By End User: Hospital Pharmacy, Retail Pharmacy, Online PharmacyFor further insights on the ischemic heart disease IHD drugs market, request a sample here

Which region has the largest share of the ischemic heart disease IHD drugs market? What are the other regions covered in the report?

North America was the largest region in the ischemic heart disease (IHD) drugs market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the ischemic heart disease (ihd) drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. For further insights on the ischemic heart disease IHD drugs market, request a sample here.

Who are the major players in the ischemic heart disease IHD drugs market?

What are the key trends in the ischemic heart disease IHD drugs market?

Major trend in the ischemic heart disease IHD drugs market - increasing focus on developing intravenous p2y12 platelet inhibitor to gain a competitive advantage. For further insights on the ischemic heart disease IHD drugs market, request a sample here.

What are the major opportunities in the ischemic heart disease IHD drugs market? What are the strategies for the ischemic heart disease IHD drugs market?

For detailed insights on the major opportunities and strategies in the ischemic heart disease IHD drugs market, request a sample here.

How does the ischemic heart disease IHD drugs market relate to the overall economy and other similar markets?

For detailed insights on ischemic heart disease IHD drugs market's relation to the overall economy and other similar markets, request a sample here.

What are the latest mergers and acquisitions in the ischemic heart disease IHD drugs industry?

For detailed insights on the mergers and acquisitions in the ischemic heart disease IHD drugs industry, request a sample here.

What are the key dynamics influencing the ischemic heart disease IHD drugs market growth? SWOT analysis of the ischemic heart disease IHD drugs market.

For detailed insights on the key dynamics influencing the ischemic heart disease IHD drugs market growth and SWOT analysis of the ischemic heart disease IHD drugs industry, request a sample here.